Next Article in Journal
Genome-Scale Analysis of Homologous Genes among Subgenomes of Bread Wheat (Triticum aestivum L.)
Next Article in Special Issue
The Role of CDKs and CDKIs in Murine Development
Previous Article in Journal
Sweet Cherry (Prunus avium L.) PaPIP1;4 Is a Functional Aquaporin Upregulated by Pre-Harvest Calcium Treatments that Prevent Cracking
Previous Article in Special Issue
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Review

CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets

1
Molecular Medicine Graduate Program, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
2
The Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa, 2-570 Bowen Science Bldg., Iowa City, IA 52242, USA
3
The Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
4
The Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
5
The Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(8), 3018; https://doi.org/10.3390/ijms21083018
Received: 6 April 2020 / Revised: 20 April 2020 / Accepted: 22 April 2020 / Published: 24 April 2020
(This article belongs to the Special Issue Cyclin-Dependent Kinases in Health and Diseases)
Sarcomas represent one of the most challenging tumor types to treat due to their diverse nature and our incomplete understanding of their underlying biology. Recent work suggests cyclin-dependent kinase (CDK) pathway activation is a powerful driver of sarcomagenesis. CDK proteins participate in numerous cellular processes required for normal cell function, but their dysregulation is a hallmark of many pathologies including cancer. The contributions and significance of aberrant CDK activity to sarcoma development, however, is only partly understood. Here, we describe what is known about CDK-related alterations in the most common subtypes of sarcoma and highlight areas that warrant further investigation. As disruptions in CDK pathways appear in most, if not all, subtypes of sarcoma, we discuss the history and value of pharmacologically targeting CDKs to combat these tumors. The goals of this review are to (1) assess the prevalence and importance of CDK pathway alterations in sarcomas, (2) highlight the gap in knowledge for certain CDKs in these tumors, and (3) provide insight into studies focused on CDK inhibition for sarcoma treatment. Overall, growing evidence demonstrates a crucial role for activated CDKs in sarcoma development and as important targets for sarcoma therapy. View Full-Text
Keywords: cyclin-dependent kinase; sarcoma; cell cycle; therapeutics; retinoblastoma protein; CDK inhibitors cyclin-dependent kinase; sarcoma; cell cycle; therapeutics; retinoblastoma protein; CDK inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Kohlmeyer, J.L.; Gordon, D.J.; Tanas, M.R.; Monga, V.; Dodd, R.D.; Quelle, D.E. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. Int. J. Mol. Sci. 2020, 21, 3018. https://doi.org/10.3390/ijms21083018

AMA Style

Kohlmeyer JL, Gordon DJ, Tanas MR, Monga V, Dodd RD, Quelle DE. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences. 2020; 21(8):3018. https://doi.org/10.3390/ijms21083018

Chicago/Turabian Style

Kohlmeyer, Jordan L., David J. Gordon, Munir R. Tanas, Varun Monga, Rebecca D. Dodd, and Dawn E. Quelle. 2020. "CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets" International Journal of Molecular Sciences 21, no. 8: 3018. https://doi.org/10.3390/ijms21083018

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop